cardiac proarrhythmic risk assessment using human ipsc-derived cardiomyocytes - session 2
Published 2 years ago • 625 plays • Length 42:06Download video MP4
Download video MP3
Similar videos
-
40:13
cardiac proarrhythmic risk assessment using human ipsc-derived cardiomyocytes - session 1
-
50:56
high-throughput assessment of compound-induced cardiotoxicity using human ipsc-derived cardiomyocyte
-
21:40
validation of htp assays using human ipsc-derived cardiomyocytes to assess cardiotoxic compounds
-
47:54
eurofins integrated cardiac proarrythmic risk assessment under the cipa initiative
-
36:18
integrated cardiac proarrythmic risk assessment under the cipa initative [2020 jsps seminar]
-
2:01
human ipsc-derived cardiomyocyte networks for recurrent ap recordings
-
57:01
exploring the role of ipsc-cardiomyocytes in drug discovery and safety assessment
-
6:43:27
research ins]i[ghts cardiac safety symposium 2021
-
57:01
webinar: exploring the role of ipsc-cardiomyocytes in drug discovery and safety assessment
-
59:39
cipa initiative and validation of high-throughput methods to characterize compound effects
-
0:37
cardioversion for atrial fibrillation
-
4:16
esc tv at acc.19 - smart-choice
-
3:15
r series plus: synchronized cardioversion
-
7:09
in silico modeling for the new cipa paradigm
-
1:44
esc 2015: anticoagulants in atrial fibrillation – how to identify high risk patients - niessner
-
2:09
esc tv at hf 2018-upgrades from a previous device compared to de novo crt implantation
-
8:26
esc tv 2015 - ehra - contemporary management of atrial fibrillation
-
4:01
tests for measuring risk of heart failure
-
1:13
r series plus (software prior to v 14)